Metastatic Merkel Cell Carcinoma: Resisting the Urge to Bridge with Chemotherapy
A single patient with a violently fast-growing cancer and a liver that may not have time to wait for the treatment everyone agrees works best. The disagreement is whether speed itself is reason enough to spend a chemotherapy option first.
V.A., a 79-year-old woman, has kept the same vegetable garden going every summer for over forty years, and only stopped weeding it three weeks ago when a violaceous nodule on her scalp -- present for barely a month -- had grown enough that her daughter insisted on a same-week dermatology visit. Biopsy confirmed Merkel cell carcinoma, and staging imaging found nodal disease plus three hepatic lesions, the largest 4.1cm, with a total bilirubin already creeping upward at 1.6, still shy of frank obstruction but a real early signal in a cancer known for growing this fast.
Merkel cell carcinoma is one of oncology's most reliably immunogenic solid tumors, and first-line anti-PD-1 therapy reflects that: CITN-09/KEYNOTE-017, Nghiem's first-line pembrolizumab trial, reported a 56 percent objective response rate, with a meaningful fraction proving durable years out -- a profile platinum-etoposide chemotherapy, this disease's older standard, has never matched despite comparable or even higher initial response rates near 60 percent, because those chemotherapy responses typically last a matter of months, not years. The instinct to reach for chemotherapy anyway, given how fast her liver values are moving, is understandable and specifically wrong for this disease: reported anti-PD-1 response rates in this disease are consistently lower in chemotherapy-pretreated patients than in treatment-naive ones — 56 percent first-line in CITN-09/KEYNOTE-017 against roughly a third in JAVELIN Merkel 200's chemotherapy-refractory cohort. That comparison sits across two trials rather than inside one, so it cannot establish that the chemotherapy caused the gap; it is enough to make spending the chemotherapy option first a bet rather than a free hedge.
Her bilirubin, read against that finding, argues for speed rather than for spending an option: time-to-response in CITN-09/KEYNOTE-017 often landed within the first six to nine weeks, faster than the disease's own general reputation for slow immunotherapy onset would suggest, and close enough to her hepatic trajectory to plausibly outrun it without detouring through a drug class that could compromise the treatment actually most likely to control her disease long-term. Her albumin remains normal and her INR is 1.0, both genuinely reassuring against a bilirubin that, while trending upward, has not yet crossed into the range where synthetic hepatic function itself is in question.
She has no history of autoimmune disease and no prior organ transplant, the two circumstances that most complicate an anti-PD-1 recommendation in other patients — a detail the team notes explicitly precisely because it removes what would otherwise be the first competing consideration in a case like hers.
Whether speed justifies a chemotherapy bridge
Merkel cell carcinoma is about as immunogenic a solid tumor as we treat, and pembrolizumab's first-line data reflect that -- 56 percent objective response in CITN-09/KEYNOTE-017, with a real fraction holding for years. And its reported time-to-response in that same trial often lands within six to nine weeks, faster than immunotherapy's general reputation would suggest. I don't think we should assume it's too slow for her before checking what the disease-specific number actually says.
Her bilirubin is 1.6 and trending upward against three hepatic lesions in a cancer that can double in size within weeks. Six to nine weeks is faster than immunotherapy's general reputation, I agree -- but it's still an eternity if her liver function is moving faster than that window allows. A short course of platinum-etoposide has a higher, faster initial response rate and could reduce that hepatic burden before it becomes obstruction.
I recognize chemotherapy's responses in this disease don't tend to last. I'm not proposing it as her whole treatment plan -- I'm proposing it as a bridge to buy the liver time to still be functioning when the durable treatment kicks in.
I understand the instinct to bridge, and in most cancers I'd take that argument seriously. Merkel cell carcinoma is where I'd be most careful about it. First-line pembrolizumab responded at 56 percent in CITN-09/KEYNOTE-017; JAVELIN Merkel 200's chemotherapy-refractory patients responded at roughly a third. I'll grant that's a cross-trial comparison and not proof of causation — but it's the wrong direction to be betting against. This isn't a generic delay cost we're weighing against speed -- it's a real risk of compromising the treatment most likely to actually control her disease long-term.
Start pembrolizumab now, with hepatic function monitored closely enough to catch true deterioration early rather than assumed inevitable. If her bilirubin genuinely crosses into obstruction before a response is visible, that's a new, different conversation about biliary intervention -- not a reason to spend the chemotherapy option first and risk the very treatment we're trying to protect.
Agreed: start pembrolizumab first-line, with hepatic function monitored at a shortened interval -- weekly rather than the usual every-three-week check -- specifically to catch true deterioration early rather than assume the disease-specific response timeline will outrun it.